Drug intelligence / Profile preview

SYS6023

Development stage: Phase 2
Lead developer: CSPC Megalith Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous Infusion

Overview

SYS6023 is a novel antibody-drug conjugate (ADC) developed by CSPC Megalith Biopharmaceutical Co.,Ltd. It targets Human epidermal growth factor receptor 3 (HER3) and is administered via intravenous infusion. It is currently being evaluated in a Phase I clinical study for its safety, tolerability, pharmacokinetic profiles, and preliminary efficacy in patients with advanced solid tumors.

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on SYS6023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYS6023.

Explore the full profile